VLS Valneva SE

VALNEVA Declaration of shares and voting rights: April 30, 2025

VALNEVA Declaration of shares and voting rights: April 30, 2025

VALNEVA

Declaration of shares and voting rights

April 30, 2025

__________________________________________________________________________________________

Company name: VALNEVA

Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)

Regulated market of Euronext Paris - Compartment B

Declaration date: May 7, 2025

Number of shares

composing the share capital of Valneva		Total number of voting rights including suspended voting rights*Description of the change Date on which this change was recognizedTotal number of voting rights excluding suspended voting rights**
167,271,524 



ordinary shares with a par value of €0.15 each		183,160,262Double voting rights granted on 784 ordinary shares









Capital increase without preferential subscription rights (4,750,000 new ordinary shares issued)		Between April 4 & April 28, 2025









On April 11, 2025		183,035,940

___________________________

* Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

** Net (or exercisable at a General Meeting) voting rights.

Attachment



EN
07/05/2025

Underlying

VLSValneva SE

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Valneva SE

 PRESS RELEASE
Free
VLS VALNEVA SE

Valneva to Participate at U.S. and European Investor Conferences in Ju...

Valneva to Participate at U.S. and European Investor Conferences in June Saint-Herblain (France), May 26, 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and hold investor meetings at several upcoming investor conferences in the United States and Europe in June 2025. Key topics for discussion include Valneva’s commercial stage vaccines and its differentiated portfolio of vaccine candidates, including VLA15, the world’s leading Lyme disease vaccine candidate. VLA15 is partnered with Pfizer and currently being...

May 26, 2025 1 EN
 PRESS RELEASE
Free
VLS VALNEVA SE

Valneva participera à différentes conférences d’investisseurs aux État...

Valneva participera à différentes conférences d’investisseurs aux États-Unis et en Europe au cours du mois de juin Saint-Herblain (France), le 26 mai 2025 – (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, annonce aujourd’hui que des membres de son équipe dirigeante effectueront des présentations et rencontreront des investisseurs à différentes conférences qui se tiendront aux États-Unis et en Europe au cours du mois de juin 2024. Les principaux sujets de discussion porteront sur les vaccins commerciaux de Valneva et son portefeuille différencié de candidats vac...

May 26, 2025 1 EN
 PRESS RELEASE
Free
VLS VALNEVA SE

Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Indiv...

Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States Saint Herblain (France), May, 12 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the U.S. Food and Drug Association (FDA) and the U.S. Centers for Disease Control and Prevention (CDC), in a joint to the medical community, have recommended a pause in the use of Valneva’s single-dose live attenuated chikungunya vaccine IXCHIQ® in elderly individuals while ongoing investigations into reported serious adverse events (SAEs) are completed. This update f...

May 12, 2025 1 EN
 PRESS RELEASE
Free
VLS VALNEVA SE

Valneva fait un point sur les recommandations d’utilisation d'IXCHIQ® ...

Valneva fait un point sur les recommandations d’utilisation d'IXCHIQ® chez les personnes âgées aux États-Unis Saint Herblain (France), le 12 mai 2025 – (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que l’agence de santé américaine Food and Drug Administration (FDA) et les centres américains de contrôle et de prévention des maladies (CDC) ont recommandé à la communauté médicale américaine dans une communication conjointe de suspendre l'utilisation du vaccin vivant atténué à dose unique contre le chikungunya de Valneva, IXCHIQ®, chez les ...

May 12, 2025 1 EN
 PRESS RELEASE
Free
VLS VALNEVA SE

VALNEVA Declaration of shares and voting rights: April 30, 2025

VALNEVA Declaration of shares and voting rights: April 30, 2025 VALNEVA Declaration of shares and voting rights April 30, 2025__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: May 7, 2025 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the change Date on which this change was recognizedTotal number of vot...

May 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch